Trade receivables increased 31.0%
Trade receivables changed +31.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Trade receivables changed +31.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +26.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +94.8% from the comparable as-filed period.
Operating cash flow changed +96.8% from the comparable as-filed period.
Operating margin changed +1472 basis points from the comparable as-filed period.
Gross margin changed +281 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed +30.5% from the comparable as-filed period.
Cash & equivalents changed +54.9% from the comparable as-filed period.
Gross profit changed +35.7% from the comparable as-filed period.
SBC / revenue changed -444 basis points from the comparable as-filed period.
Operating income changed +143.5% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
R&D / revenue changed -302 basis points from the comparable as-filed period.
Operating cash-flow margin changed +619 basis points from the comparable as-filed period.
Research & development changed +17.7% from the comparable as-filed period.
Capital expenditure changed +360.3% from the comparable as-filed period.
Free-cash-flow margin changed +596 basis points from the comparable as-filed period.
Cost of revenue changed +17.8% from the comparable as-filed period.
Current assets changed +7.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Working capital / assets changed -186 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Total assets changed +6.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Current ratio changed -14.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Shares outstanding changed -1.0% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
Stock-based compensation changed +6.1% from the comparable as-filed period.
Working capital changed +3.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Capex / revenue changed +23 basis points from the comparable as-filed period.
Receivables / revenue changed +25 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +84.0% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Operating cash flow changed +83.4% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Operating margin changed +615 basis points from the comparable as-filed period.
Operating income changed +53.7% from the comparable as-filed period.
Revenue changed +25.2% from the comparable as-filed period.
Cash & equivalents changed +57.5% from the comparable as-filed period.
SBC / revenue changed -408 basis points from the comparable as-filed period.
Gross profit changed +26.9% from the comparable as-filed period.
Gross margin changed +95 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed +18.7% from the comparable as-filed period.
Net income changed +111.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Capital expenditure changed +43.9% from the comparable as-filed period. The change ranks at the 33th percentile of 6 prior comparable changes.
Capex / revenue changed +4 basis points from the comparable as-filed period.
Stock-based compensation changed +4.1% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.